KYNTRA BIO, INC.

KYNB

KYNTRA BIO, INC.

KYNB

Insider Sentiment (TTM):

Last Purchase:2026-05-14Last Sale:2023-09-01Shares Purchased (TTM):5,500Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:929,196Shares Outstanding:4,047,000Institutional Ownership Pct.:22.96%

Earnings Market Reaction:

Filing Date:2026-08-13Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	51	37	48	118	23	34	50	131	141	106	82	121
Short Term Investments	41	50	41	-	-	-	0	0	0	72	122	130
Accounts Receivable Net Current	0	5	0	0	0	0	0	29	6	37	5	32
Inventory Net	3	3	4	4	4	3	3	24	25	27	17	41
Prepaid Expense And Other Assets Current	2	6	6	11	2	3	32	61	37	36	40	40
Assets Of Disposal Group Including Discontinued Op…	-	-	0	0	133	108	111	-	-	-	66	-
Assets Current	97	101	99	133	162	149	197	245	209	278	332	364
Restricted Cash And Cash Equivalents Noncurrent	-	-	-	-	-	-	0	2	2	2	2	2
Long Term Investments	4	8	20	3	-	-	0	-	-	-	-	-
Property Plant And Equipment Net	-	-	-	-	-	-	0	8	11	12	5	15
Equity Method Investments	-	-	-	-	-	-	-	6	7	6	5	5
Other Assets Noncurrent	0	0	0	1	1	1	1	3	3	3	3	4
Operating Lease Right Of Use Asset	-	-	-	-	-	-	0	2	61	65	65	71
Disposal Group Including Discontinued Operation As…	-	-	0	0	15	16	17	-	-	-	18	-
Assets	101	110	120	137	178	165	215	264	293	366	424	460
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	8	5	4	5	10	7	5	9	10	4	16	19
Accrued Liabilities And Other Liabilities	23	17	20	26	36	35	62	151	114	164	133	171
Contract With Customer Liability Current	5	6	5	5	27	23	27	29	10	13	13	7
Secured Debt Current	-	-	-	-	74	-	-	-	-	-	-	-
Liabilities Of Disposal Group Including Discontinu…	-	-	0	0	8	8	39	-	-	-	44	-
Liabilities Current	36	28	29	36	156	73	133	191	149	197	218	209
Operating Lease Liability Current	-	-	-	-	-	-	0	1	16	15	13	12
Contract With Customer Liability Noncurrent	3	4	0	1	122	115	115	126	131	147	158	154
Secured Long Term Debt	-	-	0	0	0	73	73	73	72	72	72	72
Other Liabilities Noncurrent	0	0	0	0	0	1	1	1	1	4	3	4
Operating Lease Liability Noncurrent	-	-	-	-	-	-	0	1	58	63	65	70
Liabilities Of Disposal Group Including Discontinu…	-	-	0	0	0	0	0	-	-	-	2	-
Liabilities	109	119	115	120	359	340	398	466	484	552	586	576
Redeemable Noncontrolling Interest Equity Carrying…	21	21	21	21	21	21	21	21	21	21	21	21
Stockholders Equity Inclu…
Common Stock Value	0	0	1	1	1	1	1	1	1	1	1	1
Additional Paid In Capital	1,680	1,679	1,677	1,676	1,673	1,671	1,669	1,668	1,661	1,652	1,644	1,634
Accumulated Other Comprehensive Income Loss Net Of…	-1	-2	-2	-2	-5	-4	-6	-6	-4	-7	-7	-7
Retained Earnings Accumulated Deficit	-1,709	-1,721	-1,706	-1,692	-1,892	-1,885	-1,889	-1,907	-1,890	-1,875	-1,842	-1,786
Stockholders Equity	-30	-31	-17	-17	-223	-196	-226	-244	-212	-208	-204	-157
Nonredeemable Noncontrolling Interest	1	13	13	13	20	20	20	20	20	20	20	20
Liabilities And Stockholders Equity	101	110	120	137	178	165	215	264	293	366	424	460
Preferred Stock Par Or Stated Value Per Share	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
Preferred Stock Shares Authorized	125	125	125	125	125	125	125	125	125	125	125	125
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
Common Stock Shares Authorized	225	225	225	225	225	225	225	225	225	225	225	225
Common Stock Shares Issued	4	4	4	4	4	4	4	4	4	4	4	4
Shares Outstanding	4	4	4	4	4	4	4	4	4	4	4	4

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-7.13%	5.61%	-6.02%	-	-	-	-	-	-	-	-	-
2025	2.62%	-26.43%	-9.64%	44.56%	40.14%	32.86%	-23.45%	-16.73%	-28.36%	2.43%	-0.71%	-4.14%
2024	3.45%	-23.08%	0.00%	-16.91%	-7.64%	-30.00%	-11.51%	41.18%	25.12%	-37.75%	-30.79%	-29.66%
2023	-	-	-	-	-	-	12.37%	58.49%	67.36%	39.46%	-37.84%	-35.14%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	2.69	3.61	3.39	3.71	1.04	2.02	1.47	1.28	1.41	1.41	1.52	1.74
Quick Ratio	2.54	3.28	3.05	3.28	1.00	1.94	1.21	0.84	0.99	1.09	1.26	1.35
Working Capital	60.79M	73.24M	69.83M	97.45M	6.43M	75.14M	63.20M	54.00M	60.87M	81.43M	113.89M	154.69M
Leverage & Debt
Debt to Equity	-3.69	-3.86	-6.77	-7.02	-1.61	-1.73	-1.94	-1.91	-2.28	-2.66	-3.19	-3.66
Interest Coverage TTM	-5.42	-5.02	-5.24	-4.61	-9.56	-13.81	-18.24	-28.39	-22.39	-23.57	-25.15	-25.37
Debt Ratio	1.08	1.08	0.96	0.87	2.02	2.06	1.86	1.76	1.65	1.51	1.38	1.25
Efficiency & Turnover
Asset Turnover TTM	0.03	0.05	0.04	0.04	0.03	0.03	0.09	-0.13	-0.02	0.08	0.09	0.29
Days Sales Outstanding TTM	19.09	127.25	19.75	641.05	162.67	971.19	34.51	-234.17	-798.63	277.44	83.52	55.37
Receivables Turnover TTM	19.12	2.87	18.48	0.57	2.24	0.38	10.58	-1.56	-0.46	1.32	4.37	6.59
Per Share Metrics
Diluted EPS TTM	45.25	40.43	45.38	53.33	-0.51	-2.48	-11.89	-30.29	-42.15	-60.73	-73.03	-74.86
Free Cash Flow Per Share TTM	-9.40	-5.29	-1.19	-4.23	-5.86	-18.88	-34.55	-31.39	-50.84	-69.37	-81.59	-89.52
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	6.28%	40.72%	91.37%	167.09%	176.03%	179.05%	47.47%	125.20%	322.09%	39.42%	91.53%	88.15%
Operating Profit Margin TTM	-1,089.78%	-602.14%	-712.66%	-476.17%	-1,113.50%	-1,660.29%	-507.80%	503.70%	3,474.67%	-821.56%	-689.53%	-189.55%
Net Profit Margin TTM	3,967.77%	2,199.42%	2,848.63%	2,598.55%	-28.12%	-143.04%	-160.63%	257.35%	2,301.08%	-667.83%	-607.29%	-189.81%
Growth Metrics
Net Revenue Growth (1Y)	-37.15%	6.33%	-78.26%	-117.54%	-200.42%	-80.57%	-36.71%	-130.54%	-105.60%	-68.98%	-66.74%	26.09%
Net Income Growth (1Y)	-8,966.99%	-1,735.01%	-485.57%	-277.07%	-98.77%	-95.84%	-83.26%	-58.60%	-47.76%	-21.71%	-3.21%	-18.64%
EPS Growth (1Y)	-8,953.85%	-1,731.37%	-481.66%	-276.06%	-98.79%	-95.92%	-83.72%	-59.54%	-48.86%	-25.11%	-6.91%	-22.35%
Valuation Metrics
P/E TTM	0.17	0.17	0.19	0.23	-10.37	-3.13	-1.11	-0.33	-0.53	-0.97	-0.30	-0.29
P/B TTM	-1.03	-0.89	-2.09	-2.91	-0.10	-0.16	-0.26	-0.16	-0.42	-1.12	-0.47	-0.54
P/S TTM	6.62	3.69	5.51	5.97	2.92	4.47	1.79	-0.85	-12.17	6.46	1.84	0.55
Market Cap	30.56M	27.44M	35.50M	49.54M	21.42M	31.29M	53.03M	40.11M	89.04M	232.61M	86.21M	84.79M
Enterprise Value	-20.08M	-9.56M	-12.37M	-68.44M	71.79M	71.10M	75.64M	-18.11M	20.81M	199.09M	76.59M	35.54M
Calculated Values
Free Cash Flow TTM	-38.06M	-21.40M	-4.81M	-17.09M	-23.69M	-76.25M	-138.27M	-126.23M	-202.99M	-274.68M	-317.54M	-351.81M
Net Debt	-50.64M	-37.00M	-47.87M	-117.98M	50.37M	39.81M	22.61M	-58.22M	-68.24M	-33.52M	-9.62M	-49.25M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-05-14Purchase

Owner: Wettig, Thane

Title: CEO

Shares: 2,800

Price/Share: $7.09

Value: $19,852.00

Shares Owned: 27,203

Relationship: Director,Officer

Ownership: Direct

2025-11-17Purchase

Owner: Wettig, Thane

Title: CEO

Shares: 2,700

Price/Share: $9.10

Value: $24,570.00

Shares Owned: 24,939

Relationship: Director,Officer

Ownership: Direct

2025-06-30Purchase

Owner: Schoeneck, James A

Title: -

Shares: 23,567

Price/Share: $5.07

Value: $119,484.69

Shares Owned: 39,666

Relationship: Director

Ownership: Indirect

2025-03-24Purchase

Owner: Wettig, Thane

Title: CEO

Shares: 145,000

Price/Share: $0.35

Value: $50,750.00

Shares Owned: 543,329

Relationship: Director,Officer

Ownership: Direct

2025-03-21Purchase

Owner: Schoeneck, James A

Title: -

Shares: 50,000

Price/Share: $0.34

Value: $17,000.00

Shares Owned: 373,722

Relationship: Director

Ownership: Indirect

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-05-14	Wettig, Thane	Director,Officer	CEO	Direct	Purchase	2,800	7.09	$19,852.00	27,203	4/A
2025-11-17	Wettig, Thane	Director,Officer	CEO	Direct	Purchase	2,700	9.10	$24,570.00	24,939	4
2025-06-30	Schoeneck, James A	Director	-	Indirect	Purchase	23,567	5.07	$119,484.69	39,666	4
2025-03-24	Wettig, Thane	Director,Officer	CEO	Direct	Purchase	145,000	0.35	$50,750.00	543,329	4
2025-03-21	Schoeneck, James A	Director	-	Indirect	Purchase	50,000	0.34	$17,000.00	373,722	4
2024-06-12	Adib, Deyaa	Officer	Chief Medical Officer	Direct	Purchase	22,123	1.17	$25,883.91	82,123	4
2024-03-07	Wettig, Thane	Officer	CEO	Direct	Purchase	50,000	1.91	$95,500.00	470,178	4
2023-09-01	Henderson, Jeffrey Willia…	Director	-	Direct	Sale	2,000	1.03	$2,060.00	28,866	4
2023-08-04	Henderson, Jeffrey Willia…	Director	-	Direct	Sale	2,000	1.91	$3,820.00	30,866	4
2023-07-11	Henderson, Jeffrey Willia…	Director	-	Direct	Sale	2,000	2.69	$5,380.00	32,866	4
2023-07-07	Conterno, Enrique A	Director,Officer	Chief Executive Officer	Direct	Sale	1,880	2.80	$5,264.00	374,722	4
2023-06-23	Wettig, Thane	Officer	Chief Commercial Officer	Direct	Sale	791	16.53	$13,075.23	108,261	4
2023-06-14	Chung, Christine	Officer	SVP, China Operations	Direct	Sale	6,250	17.06	$106,625.00	236,327	4
2023-06-09	Brennan, Aoife	Director	-	Direct	Sale	4,733	17.13	$81,076.29	27,947	4
2023-06-09	Cravatt, Benjamin	Director	-	Direct	Sale	3,944	17.13	$67,560.72	28,736	4
2023-06-09	Blaug, Suzanne	Director	-	Direct	Sale	8,520	17.12	$145,862.40	29,594	4
2023-06-09	Edwards, Jeffrey L	Director	-	Direct	Sale	7,889	17.12	$135,059.68	33,977	4
2023-06-08	Ho, Maykin	Director	-	Direct	Sale	8,520	17.24	$146,884.80	31,501	4
2023-06-08	Henderson, Jeffrey Willia…	Director	-	Direct	Sale	7,000	17.28	$120,960.00	34,866	4
2023-06-07	Schoeneck, James A	Director	-	Indirect	Sale	7,100	18.03	$128,013.00	73,722	4
2023-06-07	Wettig, Thane	Officer	Chief Commercial Officer	Direct	Sale	1,758	17.04	$29,956.32	109,052	4/A
2023-06-07	Graham, Juan	Officer	Chief Financial Officer	Direct	Sale	1,785	16.99	$30,327.15	71,083	4
2023-06-07	Chung, Christine	Officer	SVP, China Operations	Direct	Sale	3,633	17.04	$61,906.32	248,827	4
2023-06-07	Eisner, Mark	Officer	EVP, Chief Medical Officer	Direct	Sale	2,042	17.04	$34,795.68	162,862	4
2023-06-07	Conterno, Enrique A	Director,Officer	Chief Executive Officer	Direct	Sale	8,897	17.04	$151,604.88	376,602	4
2023-06-02	Eisner, Mark	Officer	EVP, Chief Medical Officer	Direct	Sale	1,090	18.83	$20,524.70	164,904	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

22.96%

Inst. Shares: 929,196

Shares Outstanding: 4,047,000

2025-12-31

25.86%

Inst. Shares: 1,045,389

Shares Outstanding: 4,043,000

2025-09-30

25.28%

Inst. Shares: 1,022,147

Shares Outstanding: 4,044,000

2025-06-30

22.42%

Inst. Shares: 906,123

Shares Outstanding: 4,042,000

2025-03-31

Inst. Shares: 28,862,869

Shares Outstanding: 4,038,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	929,196	4,047,000	22.96%
2025-12-31	1,045,389	4,043,000	25.86%
2025-09-30	1,022,147	4,044,000	25.28%
2025-06-30	906,123	4,042,000	22.42%
2025-03-31	28,862,869	4,038,000	-
2024-12-31	31,967,606	4,002,000	-
2024-09-30	40,681,005	4,021,000	-
2024-06-30	51,336,893	3,993,000	-
2024-03-31	58,148,997	3,959,280	-
2023-12-31	65,917,369	3,892,120	-
2023-09-30	65,896,282	3,929,800	-
2023-06-30	75,054,339	3,909,160	-
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

KYNTRA BIO, INC. (KYNB) — SEC Financial Statements & Analysis

KYNTRA BIO, INC. (KYNB) is a pharmaceutical preparations company. KYNTRA BIO, INC. trades on Nasdaq as: KYNB. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), KYNTRA BIO, INC. reported a -37.15% year-over-year revenue growth, a Gross Profit Margin of 6.28% (TTM), a Debt-to-Equity ratio of -3.69x, a Price-to-Sales (P/S) ratio of 6.62x (TTM), a Price-to-Book (P/B) ratio of -1.03x (TTM), at a market cap of $30.56M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -37.15%
Gross Profit Margin TTM: 6.28%
Debt To Equity: -3.69x
P/S TTM: 6.62x
P/B TTM: -1.03x
Market Cap: $30.56M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is KYNTRA BIO, INC. in?

KYNTRA BIO, INC. (KYNB) operates in the Pharmaceutical Preparations industry.

What is KYNB's market cap?

KYNTRA BIO, INC. (KYNB) has a market capitalization of $30.56M as of 2026-06-30.

What is KYNB's P/E ratio?

KYNTRA BIO, INC. (KYNB)'s trailing twelve month P/E ratio is 0.17x as of 2026-06-30.

What exchange does KYNB trade on?

KYNTRA BIO, INC. (KYNB) trades on the Nasdaq.

KYNTRA BIO, INC.

Financial Statements

Custom Table

Interactive Financial Visualizations

Earnings Market Reaction

Performance and Valuation Metrics

Insider Transactions

Institutional Ownership

KYNTRA BIO, INC. (KYNB) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Pharmaceutical Preparations

Wall Street's data.
Main Street's price.

KYNTRA BIO, INC. (KYNB) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Pharmaceutical Preparations

Wall Street's data.Main Street's price.

Wall Street's data.
Main Street's price.